Clinical stage-depending decrease of NK cell activity in multiple myeloma patients
- PMID: 17873307
- DOI: 10.1007/s12032-007-0007-y
Clinical stage-depending decrease of NK cell activity in multiple myeloma patients
Abstract
Natural killer cells, as an important subpopulation of cells of the innate immune system have an essential role in defense of the rise and spread of malignancy. These cells have a CD3-CD16 + CD56+ phenotype and they are functionally defined by their ability to lyses tumor cells. We here show that decrease of NK cell activity was significantly associated with advanced clinical stage, increased lactate dehydrogenase (LDH), percentage infiltration of bone marrow with plasma cells, and beta-2 microglobulin. The patients with higher NK cell activity at presentation after receiving VAD protocol have better cumulative survival in comparison with those with low NK cell activity.
Similar articles
-
[Preliminary report of fludarabine, mitoxantrone and dexamethasone in treating refractory or relapsed multiple myeloma].Ai Zheng. 2005 Dec;24(12):1518-21. Ai Zheng. 2005. PMID: 16351805 Chinese.
-
Multiple Myeloma Impairs Bone Marrow Localization of Effector Natural Killer Cells by Altering the Chemokine Microenvironment.Cancer Res. 2015 Nov 15;75(22):4766-77. doi: 10.1158/0008-5472.CAN-15-1320. Epub 2015 Oct 5. Cancer Res. 2015. PMID: 26438594
-
The interaction of maintenance interferon with cytolytic cells in patients with multiple myeloma who responded to cytotoxic chemotherapy.Pharmacotherapy. 1997 Mar-Apr;17(2):248-55. Pharmacotherapy. 1997. PMID: 9085315 Clinical Trial.
-
Mechanisms of NK Cell Activation and Clinical Activity of the Therapeutic SLAMF7 Antibody, Elotuzumab in Multiple Myeloma.Front Immunol. 2018 Nov 5;9:2551. doi: 10.3389/fimmu.2018.02551. eCollection 2018. Front Immunol. 2018. PMID: 30455698 Free PMC article. Review.
-
Functional subsets of mouse natural killer cells.Immunol Rev. 2006 Dec;214:47-55. doi: 10.1111/j.1600-065X.2006.00454.x. Immunol Rev. 2006. PMID: 17100875 Review.
Cited by
-
Reduced immune effector cell NKG2D expression and increased levels of soluble NKG2D ligands in multiple myeloma may not be causally linked.Cancer Immunol Immunother. 2010 Jun;59(6):829-39. doi: 10.1007/s00262-009-0807-3. Epub 2009 Dec 19. Cancer Immunol Immunother. 2010. PMID: 20024547 Free PMC article.
-
Immunophenotypic Characteristics of Bone Marrow Microenvironment Cellular Composition at the Biochemical Progression of Multiple Myeloma.J Clin Med. 2022 Jun 27;11(13):3722. doi: 10.3390/jcm11133722. J Clin Med. 2022. PMID: 35807007 Free PMC article.
-
The yin-yang effects of immunity: From monoclonal gammopathy of undetermined significance to multiple myeloma.Front Immunol. 2022 Jul 25;13:925266. doi: 10.3389/fimmu.2022.925266. eCollection 2022. Front Immunol. 2022. PMID: 35958625 Free PMC article. Review.
-
Predictive Role of Immune Profiling for Survival of Multiple Myeloma Patients.Front Immunol. 2021 Jul 5;12:663748. doi: 10.3389/fimmu.2021.663748. eCollection 2021. Front Immunol. 2021. PMID: 34290698 Free PMC article. Review.
-
Increased Levels of CD107a and Intracellular Cytokines in IL-2 Stimulated PBMCs from Endometriosis Patients.Int J Inflam. 2021 Sep 27;2021:5760959. doi: 10.1155/2021/5760959. eCollection 2021. Int J Inflam. 2021. PMID: 34616540 Free PMC article.
References
Publication types
MeSH terms
Substances
Supplementary concepts
LinkOut - more resources
Full Text Sources
Medical
Research Materials